Immunocellular Thera (IMUC) 0.97 $IMUC
Biotechnology Sector in Focus
ACCESSWIRE - Thu Jul 31, 8:01AM CDT
Deerfield Beach, FL / ACCESSWIRE / July 31, 2014 / One of the major concerns for big pharma is patent expirations. Patent expirations will result in a loss of $34 billion in revenue at big pharma companies this year. This was after pharma companies lost $55 billion and $28 billion in revenue in 2012 and 2013, respectively. In 2015, products worth $66 billion will see their patents expire.
ImmunoCellular Therapeutics to Report Financial Results for the Second Quarter 2014 on August 7, 2014
PR Newswire - Tue Jul 29, 3:01PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that it plans to report second quarter 2014 financial results on Thursday, August 7, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO.
ImmunoCellular Therapeutics Up 8.6%, Shares Break Through Resistance (IMUC)
Comtex SmarTrend(R) - Wed Jul 23, 11:39AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing low-priced stocks, up 8.6% to $1.01 on 1.2x average daily volume. ImmunoCellular Therapeutics has traded 936,000 shares thus far today, vs. average volume of 802,000 shares per day. The stock has outperformed the Dow (8.6% to the Dow's -0.2%) and outperformed the S&P 500 (8.6% to the S&P's 0.2%) during today's trading.
Equities to Watch in the Health Care Sector -- ImmunoCellular Therapeutics, Aeterna Zentaris, Lexicon Pharma, BioDelivery Sciences Intl., and Jazz Pharma
PR Newswire - Wed Jul 23, 7:40AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.75, up 0.83%, with the index also advancing 5.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC), Aeterna Zentaris Inc. (NASDAQ: AEZS), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
Investors look to Lighten Up on Shares of ImmunoCellular Therapeutics, Shares Down 9.1% (IMUC)
Comtex SmarTrend(R) - Wed Jul 16, 12:42PM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 9.1% to $0.96 on 1.1x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 1.0 million shares, vs. average volume of 952,000 shares per day. The stock has underperformed the Dow (-9.1% to the Dow's 0.4%) and underperformed the S&P 500 (-9.1% to the S&P's 0.4%) during today's trading.
Theralase's Cancer Technology Demonstrates Vaccine-Like Properties
ACCESSWIRE - Mon Jun 16, 7:04AM CDT
Whitefish, MT / June 16, 2014 / Conventional cancer treatment involves surgically removing cancerous tumors and then killing the remaining cells with toxic chemotherapy drugs. Unfortunately, these approaches involve invasive surgeries and the indiscriminant killing of cells that lead to the immune system being compromised. The success rates for these treatments, particularly in later stage cancers, also leave a lot to be desired.
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
M2 - Thu Jun 05, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jll46/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany" report to their offering. During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck's Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. The market entry of Northwest Biotherapeutics' DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline. Scope - A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis - In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy - A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target - Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate - Multi-scenario forecast data for the GBM market to 2019, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain - Discussion of the drivers of and barriers to market growth - Discussion of the licensing and co-development deals landscape in GBM Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed drugs - Temodar (temozolomide) - Merck - Avastin (bevacizumab) - Roche - BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan) - BiCNU (carmustine) - Bristol-Myers Squibb - Gliadel Wafer (carmustine in polifeprosan) - Eisai - Lomustine - Carboplatin - Cyclophosphamide - Etoposide - Irinotecan 4 Glioblastoma Pipeline - DCVax-L - Northwest Biotherapeutics - Rindopepimut (CDX-110) - Celldex Therapeutics - Avastin (bevacizumab)- Roche - ICT-107 - ImmunoCellular Therapeutics - Cotara- Peregrine Pharmaceuticals - Eir-060- EirGen Pharma - Heat Map of Safety and Efficacy and Competitor Matrix for Glioblastoma Multiforme Pipeline 5 Market forecasts 6 Deals and Strategic Consolidations - Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical - Immatics Biotechnologies Enters into Agreement with Cancer Research UK - ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania - Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children's Hospital Medical Center - Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center 7 Appendix For more information visit http://www.researchandmarkets.com/research/4j...ioblastoma
Upgrade Alert for ImmunoCellular Therapeutics (IMUC)
Comtex SmarTrend(R) - Tue Jun 03, 6:59AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) was upgraded from Neutral to Buy at Roth Capital today. The stock closed yesterday at $1.15 on volume of 4.5 million shares, above average daily volume of 595,000. ImmunoCellular Therapeutics has overhead space with shares priced $1.15, or 79.8% below the average consensus analyst price target of $5.69. The stock should run into initial resistance at its 50-day moving average (MA) of $1.23 and subsequent resistance at its 200-day MA of $1.84.
Stock to Watch: ImmunoCellular Therapeutics Down 8.2% (IMUC)
Comtex SmarTrend(R) - Mon Jun 02, 10:39AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing low-priced stocks, down 8.2% to $1.23 on 4.2x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 2.5 million shares, vs. average volume of 595,000 shares per day. The stock has underperformed the Dow (-8.2% to the Dow's 0.2%) and underperformed the S&P 500 (-8.2% to the S&P's 0.1%) during today's trading.
ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at the 2014 ASCO Annual Meeting
PR Newswire - Sun Jun 01, 6:30AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT:IMUC) announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical Oncology (ASCO) annual meeting in Chicago.
5 Stocks Poised for Breakouts
at The Street - Tue May 27, 7:11AM CDT
These stocks look ready to break out and trade higher from current levels.
4 Stocks Under $10 to Trade for Breakouts
at The Street - Wed May 21, 7:41AM CDT
These under-$10 stocks are within range of triggering breakout trades.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 20, 1:26PM CDT
These under-$10 stocks look ready to trade higher from current levels.
Technical Notes on Top Gainers -- Research on Sequenom, ImmunoCellular Therapeutics, Intellicheck Mobilisa, and La Jolla Pharma
PR Newswire - Thu Mar 20, 7:33AM CDT
On Wednesday, March 19, 2014, the US markets saw a negative sentiment with the NASDAQ Composite closing at 4,307.60, down 0.59%, the Dow Jones Industrial Average ending the session at 16,222.17, down 0.70% and the S&P 500 edging 0.61% lower to finish the trading session at 1,860.77. The losses were broad based as all the ten sectors ended the session in negative. A number of stocks saw large movements, including Sequenom Inc. (NASDAQ: SQNM), ImmunoCellular Therapeutics Ltd (AMEX: IMUC), Intellicheck Mobilisa Inc. (AMEX: IDN), and La Jolla Pharmaceutical Co. (NASDAQ: LJPC). Free technical research on SQNM, IMUC, IDN, and LJPC can be downloaded upon signing up at:
Traders Get Bullish on Shares of ImmunoCellular Therapeutics, Shares Up 5.9% (IMUC)
Comtex SmarTrend(R) - Wed Mar 19, 11:41AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing low-priced stocks, up 5.9% to $1.36 on 1.1x average daily volume. ImmunoCellular Therapeutics has traded 1.9 million shares thus far today, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (5.9% to the Dow's -0.0%) and outperformed the S&P 500 (5.9% to the S&P's -0.0%) during today's trading.
ImmunoCellular Therapeutics incurs lower net loss of USD8.8m in 2013
M2 - Fri Mar 14, 4:15AM CDT
Biotechnology company ImmunoCellular Therapeutics (NYSE MKT:IMUC) stated on Thursday its net loss of USD8.8m (USD0.16 per basic and diluted share) for the year ended 31 December 2013.
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Mar 13, 3:00PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced financial results for the quarter and year ended December 31, 2013.
ImmunoCellular Therapeutics Announces Change to Meeting Date for Annual Meeting of Stockholders
PR Newswire - Tue Mar 11, 3:15PM CDT
ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) ("ImmunoCellular" or the "Company" today announced that it will hold its 2014 Annual Meeting of Stockholders on Friday, June 13, 2014. Because the expected meeting date for the 2014 Annual Meeting represents a change of more than thirty days from the anniversary of the Company's 2013 annual meeting of stockholders held on September 20, 2013, the Company has set a new deadline for the receipt of stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act" for inclusion in the Company's proxy materials for the 2014 Annual Meeting. In order to be considered timely, such proposals must comply with the stockholder proposal requirements set forth in the Company's Bylaws and be received by the Company on or before April 15, 2014 at its principal office at 23622 Calabasas Road, Suite 300, Calabasas, California 91302, Attention: Corporate Secretary.
3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 07, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 13, 2014
PR Newswire - Tue Mar 04, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that it plans to report fourth quarter and full year 2013 financial results on Thursday, March 13, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO.
Biotechnology Sector in Focus
ACCESSWIRE - Thu Jul 31, 8:01AM CDT
Deerfield Beach, FL / ACCESSWIRE / July 31, 2014 / One of the major concerns for big pharma is patent expirations. Patent expirations will result in a loss of $34 billion in revenue at big pharma companies this year. This was after pharma companies lost $55 billion and $28 billion in revenue in 2012 and 2013, respectively. In 2015, products worth $66 billion will see their patents expire.
ImmunoCellular Therapeutics to Report Financial Results for the Second Quarter 2014 on August 7, 2014
PR Newswire - Tue Jul 29, 3:01PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that it plans to report second quarter 2014 financial results on Thursday, August 7, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO. ImmunoCellular Therapeutics Up 8.6%, Shares Break Through Resistance (IMUC)
Comtex SmarTrend(R) - Wed Jul 23, 11:39AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing low-priced stocks, up 8.6% to $1.01 on 1.2x average daily volume. ImmunoCellular Therapeutics has traded 936,000 shares thus far today, vs. average volume of 802,000 shares per day. The stock has outperformed the Dow (8.6% to the Dow's -0.2%) and outperformed the S&P 500 (8.6% to the S&P's 0.2%) during today's trading.
Equities to Watch in the Health Care Sector -- ImmunoCellular Therapeutics, Aeterna Zentaris, Lexicon Pharma, BioDelivery Sciences Intl., and Jazz Pharma
PR Newswire - Wed Jul 23, 7:40AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.75, up 0.83%, with the index also advancing 5.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC), Aeterna Zentaris Inc. (NASDAQ: AEZS), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
Investors look to Lighten Up on Shares of ImmunoCellular Therapeutics, Shares Down 9.1% (IMUC)
Comtex SmarTrend(R) - Wed Jul 16, 12:42PM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 9.1% to $0.96 on 1.1x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 1.0 million shares, vs. average volume of 952,000 shares per day. The stock has underperformed the Dow (-9.1% to the Dow's 0.4%) and underperformed the S&P 500 (-9.1% to the S&P's 0.4%) during today's trading.
Theralase's Cancer Technology Demonstrates Vaccine-Like Properties
ACCESSWIRE - Mon Jun 16, 7:04AM CDT
Whitefish, MT / June 16, 2014 / Conventional cancer treatment involves surgically removing cancerous tumors and then killing the remaining cells with toxic chemotherapy drugs. Unfortunately, these approaches involve invasive surgeries and the indiscriminant killing of cells that lead to the immune system being compromised. The success rates for these treatments, particularly in later stage cancers, also leave a lot to be desired.
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
M2 - Thu Jun 05, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jll46/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany" report to their offering. During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck's Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. The market entry of Northwest Biotherapeutics' DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline. Scope - A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis - In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy - A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target - Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate - Multi-scenario forecast data for the GBM market to 2019, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain - Discussion of the drivers of and barriers to market growth - Discussion of the licensing and co-development deals landscape in GBM Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed drugs - Temodar (temozolomide) - Merck - Avastin (bevacizumab) - Roche - BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan) - BiCNU (carmustine) - Bristol-Myers Squibb - Gliadel Wafer (carmustine in polifeprosan) - Eisai - Lomustine - Carboplatin - Cyclophosphamide - Etoposide - Irinotecan 4 Glioblastoma Pipeline - DCVax-L - Northwest Biotherapeutics - Rindopepimut (CDX-110) - Celldex Therapeutics - Avastin (bevacizumab)- Roche - ICT-107 - ImmunoCellular Therapeutics - Cotara- Peregrine Pharmaceuticals - Eir-060- EirGen Pharma - Heat Map of Safety and Efficacy and Competitor Matrix for Glioblastoma Multiforme Pipeline 5 Market forecasts 6 Deals and Strategic Consolidations - Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical - Immatics Biotechnologies Enters into Agreement with Cancer Research UK - ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania - Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children's Hospital Medical Center - Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center 7 Appendix For more information visit http://www.researchandmarkets.com/research/4j...ioblastoma
Upgrade Alert for ImmunoCellular Therapeutics (IMUC)
Comtex SmarTrend(R) - Tue Jun 03, 6:59AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) was upgraded from Neutral to Buy at Roth Capital today. The stock closed yesterday at $1.15 on volume of 4.5 million shares, above average daily volume of 595,000. ImmunoCellular Therapeutics has overhead space with shares priced $1.15, or 79.8% below the average consensus analyst price target of $5.69. The stock should run into initial resistance at its 50-day moving average (MA) of $1.23 and subsequent resistance at its 200-day MA of $1.84.
Stock to Watch: ImmunoCellular Therapeutics Down 8.2% (IMUC)
Comtex SmarTrend(R) - Mon Jun 02, 10:39AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing low-priced stocks, down 8.2% to $1.23 on 4.2x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 2.5 million shares, vs. average volume of 595,000 shares per day. The stock has underperformed the Dow (-8.2% to the Dow's 0.2%) and underperformed the S&P 500 (-8.2% to the S&P's 0.1%) during today's trading.
ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at the 2014 ASCO Annual Meeting
PR Newswire - Sun Jun 01, 6:30AM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT:IMUC) announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical Oncology (ASCO) annual meeting in Chicago. 5 Stocks Poised for Breakouts
at The Street - Tue May 27, 7:11AM CDT
These stocks look ready to break out and trade higher from current levels.
4 Stocks Under $10 to Trade for Breakouts
at The Street - Wed May 21, 7:41AM CDT
These under-$10 stocks are within range of triggering breakout trades.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 20, 1:26PM CDT
These under-$10 stocks look ready to trade higher from current levels.
Technical Notes on Top Gainers -- Research on Sequenom, ImmunoCellular Therapeutics, Intellicheck Mobilisa, and La Jolla Pharma
PR Newswire - Thu Mar 20, 7:33AM CDT
On Wednesday, March 19, 2014, the US markets saw a negative sentiment with the NASDAQ Composite closing at 4,307.60, down 0.59%, the Dow Jones Industrial Average ending the session at 16,222.17, down 0.70% and the S&P 500 edging 0.61% lower to finish the trading session at 1,860.77. The losses were broad based as all the ten sectors ended the session in negative. A number of stocks saw large movements, including Sequenom Inc. (NASDAQ: SQNM), ImmunoCellular Therapeutics Ltd (AMEX: IMUC), Intellicheck Mobilisa Inc. (AMEX: IDN), and La Jolla Pharmaceutical Co. (NASDAQ: LJPC). Free technical research on SQNM, IMUC, IDN, and LJPC can be downloaded upon signing up at:
Traders Get Bullish on Shares of ImmunoCellular Therapeutics, Shares Up 5.9% (IMUC)
Comtex SmarTrend(R) - Wed Mar 19, 11:41AM CDT
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing low-priced stocks, up 5.9% to $1.36 on 1.1x average daily volume. ImmunoCellular Therapeutics has traded 1.9 million shares thus far today, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (5.9% to the Dow's -0.0%) and outperformed the S&P 500 (5.9% to the S&P's -0.0%) during today's trading.
ImmunoCellular Therapeutics incurs lower net loss of USD8.8m in 2013
M2 - Fri Mar 14, 4:15AM CDT
Biotechnology company ImmunoCellular Therapeutics (NYSE MKT:IMUC) stated on Thursday its net loss of USD8.8m (USD0.16 per basic and diluted share) for the year ended 31 December 2013.
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Mar 13, 3:00PM CDT
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced financial results for the quarter and year ended December 31, 2013. ImmunoCellular Therapeutics Announces Change to Meeting Date for Annual Meeting of Stockholders
PR Newswire - Tue Mar 11, 3:15PM CDT
ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) ("ImmunoCellular" or the "Company"
today announced that it will hold its 2014 Annual Meeting of Stockholders on Friday, June 13, 2014. Because the expected meeting date for the 2014 Annual Meeting represents a change of more than thirty days from the anniversary of the Company's 2013 annual meeting of stockholders held on September 20, 2013, the Company has set a new deadline for the receipt of stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act" for inclusion in the Company's proxy materials for the 2014 Annual Meeting. In order to be considered timely, such proposals must comply with the stockholder proposal requirements set forth in the Company's Bylaws and be received by the Company on or before April 15, 2014 at its principal office at 23622 Calabasas Road, Suite 300, Calabasas, California 91302, Attention: Corporate Secretary. 3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 07, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 13, 2014
PR Newswire - Tue Mar 04, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that it plans to report fourth quarter and full year 2013 financial results on Thursday, March 13, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO. 
